Platelet adhesion mediated by von Willebrand factor in patients with premature coronary artery disease

Aim    To study platelet adhesion mediated by von Willebrand factor (VWF) in patients with premature ischemic heart disease (IHD).
Material and methods    This study enrolled 58 patients with stable IHD, including 45 men younger than 55 years with the first manifestation of IHD at the age of <50 years and 13 women younger than 65 years with the first manifestation of IHD at the age of <60 years. The control group consisted of 33 patients, 13 men younger than 55 years and 20 women younger than 65 years without IHD. Platelet adhesion to the collagen surface at the shear rate of 1300 s-1 was studied by evaluating the intensity of scattered laser light from the collagen-coated optical substrate in a flow chamber of a microfluidic device after 15-min circulation of whole blood in the chamber. Decreases in platelet adhesion after addition to the blood of monoclonal antibodies (mAb) to platelet receptors glycoproteins Ib (GPIb) to inhibit the receptor interaction with VWF were compared for patients of both groups. 
Results    In patients with premature IHD, the decrease in platelet adhesion following the platelet GPIb receptor inhibition was significantly less than in patients of the control group (74.8 % (55.6; 82.7) vs. 28.9 % (–9.8; 50,5), p <0.001). For the entire sample, the median decrease in platelet adhesion following the GPIb receptor inhibition was 62.8 % (52.2; 71.2). With an adjustment for traditional risk factors of IHD, a decrease in platelet adhesion of >62.8% after blocking GPIb receptors increased the likelihood of premature IHD (OR=9.84, 95 % CI: 2.80–34.59; p <0.001).
Conclusion    Blocking the interaction of GPIb receptors with VWF in patients with premature IHD and increased shear rate induced a greater decrease in platelet adhesion than in patients without this disease. This suggested that an excessive interaction of VWF with platelets might contribute to the pathogenesis of premature IHD.

1. Gulati R, Behfar A, Narula J, Kanwar A, Lerman A, Cooper L et al. Acute Myocardial Infarction in Young Individuals. Mayo Clinic Proceedings. 2020;95(1):136–56. DOI: 10.1016/j.mayocp.2019.05.001

2. Zeitouni M, Clare RM, Chiswell K, Abdulrahim J, Shah N, Pagidipati NP et al. Risk Factor Burden and Long‐Term Prognosis of Patients With Premature Coronary Artery Disease. Journal of the American Heart Association. 2020;9(24):e017712. DOI: 10.1161/JAHA.120.017712

3. Neeland IJ, Patel RS, Eshtehardi P, Dhawan S, McDaniel MC, Rab ST et al. Coronary angiographic scoring systems: An evaluation of their equivalence and validity. American Heart Journal. 2012;164(4):547-552.e1. DOI: 10.1016/j.ahj.2012.07.007

4. Gabbasov ZA, Avtaeva YN, Melnikov IS, Okhota SD, Caprnda M, Mozos I et al. Kinetics of platelet adhesion to a fibrinogen‐coated surface in whole blood under flow conditions. Journal of Clinical Laboratory Analysis. 2021;35(9):e23939. DOI: 10.1002/jcla.23939

5. Avtaeva Yu.N., Mel’nikov I.S., Gabbasov Z.A. Real-Time Recording of Platelet Adhesion to Fibrinogen-Coated Surface under Flow Conditions. Bulletin of Experimental Biology and Medicine. 2018;165(1):157–60. DOI: 10.1007/s10517-018-4119-5

6. Rana A, Westein E, Niego B, Hagemeyer CE. Shear-Dependent Platelet Aggregation: Mechanisms and Therapeutic Opportunities. Frontiers in Cardiovascular Medicine. 2019;6:141. DOI: 10.3389/fcvm.2019.00141

7. Lancellotti S, Sacco M, Basso M, Cristofaro RD. Mechanochemistry of von Willebrand factor. Biomolecular Concepts. 2019;10(1):194–208. DOI: 10.1515/bmc-2019-0022

8. Stuklov N.I., Kobelevskaya N.V., Polikarpova T.S., Chistyakova A.V., Ogurtsov P.P. Physiology and pathology of hemostasis.-M.: GEOTAR-Media;2016. - 112 p. ISBN 978-5-9704-3625-7

9. Avdonin P.P., Tsvetaeva N.V., Goncharov N.V., Rybakova E.Yu., Trufanov S.K., Citrina A.A. et al. Von Willebrand factor in norm and pathology. Membrane and Cell Biology. 2021;38(4):237–56. DOI: 10.31857/S0233475521040034

10. Rutten B, Maseri A, Cianflone D, Laricchia A, Cristell N, Durante A et al. Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: A multicenter and multiethnic study. European Heart Journal: Acute Cardiovascular Care. 2015;4(1):64–74. DOI: 10.1177/2048872614534388

11. Li Y, Li L, Dong F, Guo L, Hou Y, Hu H et al. Plasma von Willebrand factor level is transiently elevated in a rat model of acute myocardial infarction. Experimental and Therapeutic Medicine. 2015;10(5):1743–9. DOI: 10.3892/etm.2015.2721

12. Chion CKNK, Doggen CJM, Crawley JTB, Lane DA, Rosendaal FR. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood. 2007;109(5):1998–2000. DOI: 10.1182/blood-2006-07-038166

13. Willeit P, Thompson A, Aspelund T, Rumley A, Eiriksdottir G, Lowe G et al. Hemostatic Factors and Risk of Coronary Heart Disease in General Populations: New Prospective Study and Updated Meta-Analyses. PLoS ONE. 2013;8(2):e55175. DOI: 10.1371/journal.pone.0055175

14. Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P et al. von Willebrand factor and coronary heart disease. Prospective study and meta-analysis. European Heart Journal. 2002;23(22):1764–70. DOI: 10.1053/euhj.2001.3237

15. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective Study of Hemostatic Factors and Incidence of Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96(4):1102–8. DOI: 10.1161/01.CIR.96.4.1102

16. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Heart. 1991;66(5):351–5. DOI: 10.1136/hrt.66.5.351

17. Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. British Journal of Haematology. 1999;105(1):110–6. PMID: 10233372

18. Ray KK, Morrow DA, Gibson CM, Murphy S, Antman EM, Braunwald E. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome. European Heart Journal. 2005;26(5):440–6. DOI: 10.1093/eurheartj/ehi104

19. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris. New England Journal of Medicine. 1995;332(10):635–41. DOI: 10.1056/NEJM199503093321003

20. Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory Testing for von Willebrand Disease: Contribution of Multimer Analysis to Diagnosis and Classification. Seminars in Thrombosis and Hemostasis. 2006;32(5):514–21. DOI: 10.1055/s-2006-947866